GLP-1semaglutideaa amyloidosisobesitynephrology

Case report links semaglutide weight loss to renal AA amyloidosis improvement

A 47-year-old man lost 47 kg; eGFR rose from 15 to 32 mL/min/1.73 m2 and serum amyloid A fell below 10 mg/L.

By Maren Holt · Senior Reporter, GLP-1

Sep 25 20:00 ETSource: Journal of nephrology

The wire

01In the Journal of Nephrology, clinicians describe a 126-kg man with biopsy-confirmed renal AA amyloidosis whose creatinine fell from 4.3 to 2.34 mg/dL and UACR from 3.4 to 1.0 g/g after semaglutide-associated weight loss.
02The authors argue severe obesity can act as the inflammatory driver of AA amyloidosis, a consideration for nephrologists weighing incretin therapy in unexplained cases.
03This is a single case and causality cannot be inferred; the patient had a prior sleeve gastrectomy and workup for autoimmune, infectious, hereditary and monoclonal causes was negative.

From the source

Renal AA amyloidosis associated with severe obesity: improvement in kidney function and proteinuria following semaglutide-associated weight loss
Journal of nephrology · 2026 Sep 26 · Atay I, Eroz E, Bayramoğlu Z et al.

Read at pubmed.ncbi.nlm.nih.gov

Source URL https://pubmed.ncbi.nlm.nih.gov/42791222/